These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

939 related items for PubMed ID: 24631288

  • 1. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.
    Exp Cell Res; 2014 May 01; 323(2):288-96. PubMed ID: 24631288
    [Abstract] [Full Text] [Related]

  • 2. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 3. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY.
    Clin Cancer Res; 2007 May 01; 13(9):2795-803. PubMed ID: 17473213
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 01; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 5. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.
    Cancer Chemother Pharmacol; 2010 Jul 01; 66(2):381-8. PubMed ID: 19921194
    [Abstract] [Full Text] [Related]

  • 6. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

  • 7. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 8. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.
    Cancer Res; 2006 Dec 01; 66(23):11389-98. PubMed ID: 17145885
    [Abstract] [Full Text] [Related]

  • 9. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb 01; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 10. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
    Jänne PA.
    Lung Cancer; 2008 Jun 01; 60 Suppl 2():S3-9. PubMed ID: 18513582
    [Abstract] [Full Text] [Related]

  • 11. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M, Lv S.
    Mol Med Rep; 2015 Apr 01; 11(4):2767-74. PubMed ID: 25483995
    [Abstract] [Full Text] [Related]

  • 12. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G.
    Cancer Res; 2007 Jul 01; 67(13):6253-62. PubMed ID: 17616683
    [Abstract] [Full Text] [Related]

  • 13. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.
    Mol Cancer Res; 2009 Oct 01; 7(10):1736-43. PubMed ID: 19808904
    [Abstract] [Full Text] [Related]

  • 14. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF, Harrison LR, Mironov A, Roberts RA, Dive C.
    J Thorac Oncol; 2010 Jun 01; 5(6):765-77. PubMed ID: 20421816
    [Abstract] [Full Text] [Related]

  • 15. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    Biochem Biophys Res Commun; 2013 Feb 15; 431(3):623-9. PubMed ID: 23266614
    [Abstract] [Full Text] [Related]

  • 16. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
    Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY.
    Cancer Res; 2006 Oct 15; 66(20):10100-11. PubMed ID: 17047074
    [Abstract] [Full Text] [Related]

  • 17. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 15; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 18. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Mar 15; 18(6):1663-71. PubMed ID: 22317763
    [Abstract] [Full Text] [Related]

  • 19. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.
    Oncol Rep; 2013 May 15; 29(5):1975-82. PubMed ID: 23440266
    [Abstract] [Full Text] [Related]

  • 20. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, Miyoshi S, Kanazawa S, Toyooka S.
    Oncol Rep; 2015 Mar 15; 33(3):1499-504. PubMed ID: 25607753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.